Mutations in the Human λ5/14.1 Gene Result in B Cell Deficiency and Agammaglobulinemia

DNA from eight unrelated patients with sporadic agammaglobulinemia was screened for mutations in λ5/14.1, VpreB, Igα, and Igβ. The patient with mutations in λ5/14.1 had the onset of recurrent otitis at 2 mo of age and was recognized to have hypogammaglobulinemia and absent B cells at 3 yr of age when he developed hemophilus meningitis complicated by arthritis. At that time he was seronegative for the T cell–dependent antigens tetanus toxoid, diphtheria toxoid, and conjugated hemophilus influenza, despite previous immunization. He also failed to make antibody to the T cell–independent antigens in blood group substances. On four evaluations since that time, the patient has never had detectable CD19⁺ B cells by routine clinical testing. At 5 yr of age, while receiving gammaglobulin replacement therapy, he had no measurable serum IgM and IgA (<8 mg/dl). He had normal numbers of T cells and normal proliferative responses to mitogens.

Genomic DNA was analyzed by single-strand conformation polymorphism (SSCP; reference 26) using the following primers to amplify λ5/14.1: exon 1, 5′-ACCAGGGCACCACTCTCTA-3′ and 5′-GTCATCCTTTCCCGCCTCT-3′; exon 2, 5′-TGGGTCACAGCCTACACACT-3′ and 5′-CAGAAGAGGGTGGGACAGC-3′; exon 3, 5′-TCTCACCCCCTCCTCTGTCC-3′ and 5′-TGCAGAGAGAGAGACCCTTCC-3′. PCR conditions were 5 min at 95°C followed by 30 cycles of 95°C for 45 s, 62°C for 30 s, and 72°C for 30 s with a final extension of 5 min at 72°C. Before electrophoresis, PCR products from exons 1 and 3 were digested with PvuII and BstUI, respectively. BstUI would be expected to cleave the functional λ5/14.1 exon 3 but not exon 3 from the pseudogenes. Sequences demonstrating altered mobility in SSCP were cloned into TA vector (Invitrogen, Carlsbad, CA) and sequenced using M13 primers. The mutations were confirmed using a second independent PCR reaction.

Reverse transcriptase PCR (RT-PCR) was used to amplify λ5/14.1 cDNA from the patient's mononuclear bone marrow cells using the primers 5′-ACGCATGTGTTTGGCAGC-3′ and 5′-GGCGTCAGGCTCAGGTA-3′. The PCR products were cloned and sequenced as above. PCR products were digested with MspI (New England Biolabs, Beverly, MA) for 2 h at 37°C and visualized by ethidium bromide staining in a 1.8% agarose gel.

Peripheral blood lymphocytes and bone marrow cells were stained using previously described techniques and reagents (5). In addition, fixed cells were stained with an IgG1 murine monoclonal anti-VpreB antibody produced in mice immunized with a recombinant human VpreB protein (Wang, Y.-H., J. Nomura, O.M. Faye-Petersen, and M.D. Cooper, manuscript in preparation).

The pre–B cell line Nalm6 was used as the source of cDNA to amplify the genes for λ5/14.1 and VpreB by RT-PCR. PCR primers for λ5/14.1 were 5′-AGGGCACCACTCTCTAGGGA-3′ and 5′-TGCAGAGAGAGAGACCCTTCC-3′, and for VpreB were 5′-GGCCACAGGAGTCAGAGCT-3′ and 5′-GATGCGTGCCTCTGCTGTCTT-3′. PCR products were cloned into the TA vector and the Pro 142Leu mutant was generated by replacing the endogenous SacI– BamHI fragment of exon 3 with that of the patient. After the sequence had been verified, the three cDNA products were cloned into the pcDNA3 expression vector (Invitrogen) that contains a CMV promoter and SV40 origin of replication.

COS7 cells were transfected with expression vectors for the normal or mutant λ5/14.1, with or without VpreB using lipofectamine (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's protocol. The cells were metabolically labeled with 0.3 mCi of ³⁵S-Translabel (ICN, Irvine, CA) for 2 h, 44 h after transfection. Labeled cells were lysed in 1% Triton X-100, 10 mM Tris (pH 8.0), 140 mM NaCl, 1% bovine hemoglobin, 0.2 U/ml aprotinin, and 1 mM PMSF. After preclearing, lysates were incubated with murine anti-VpreB or goat antilambda chain antibodies (Sigma Chemical Co., St. Louis, MO). Specific proteins were immunoprecipitated with protein G Sepharose (Pharmacia, Uppsala, Sweden) and eluted with a sample buffer containing 50 mM Tris (pH 6.8), 10% glycerol, 1% SDS, 0.001% bromophenol blue, with or without 5% 2-mercaptoethanol. Proteins were separated by 12.5% SDS-PAGE and detected by fluorography.

Genomic DNA samples from eight patients with defects in B cell development but without mutations in Btk or mu heavy chain were screened for mutations in genes that encode components of the pre–B cell receptor complex. PCR was used to amplify individual exons by flanking splice sites and the products were analyzed with SSCP. A 5-yr-old boy with <1% of the normal number of B cells and severe hypogammaglobulinemia was found to have alterations in exons 1 and 3 of the surrogate light chain gene, λ5/14.1. Although both the patient's mother and father had normal percentages of circulating CD19⁺ B cells, 6 and 10% respectively, SSCP analysis of genomic DNA from the patient's parents indicated that the abnormality in exon 1 was derived from the maternal allele and the abnormality in exon 3 was derived from the paternal allele. Both exons were cloned and sequenced.

The patient's exon 1 sequence revealed a C to T transition at codon 22, resulting in the substitution of a premature stop codon for the wild-type glutamine (Fig. 1). In exon 3, there were three basepair substitutions: T to C at nucleotide 393 (codon 131), T to C at nucleotide 420 (codon 140), and C to T at nucleotide 425 (codon 142). The first two substitutions do not change the coding sequence; however, the third results in the replacement of the wild-type proline with leucine. The proline at this site, which occurs in the loop linking the second and third strands of one of the two beta pleated sheets that compose the immunoglobulin domain (33), is conserved not only in lambda constant region domains in all species evaluated, but also in most immunoglobulin domains (11). SSCP analysis of exon 3 of λ5/14.1 in DNA from 100 individuals did not demonstrate the pattern seen in the patient's paternal allele in any other samples.

The three basepair substitutions in the paternal allele of λ5/14.1 are the same as those found at the corresponding site in exon 3 of the λ5/14.1 pseudogene, 16.1 (17; Fig. 1). To determine whether the altered sequence could be attributed to gross rearrangements within the lambda locus, DNA from the patient was digested with EcoRI and HindIII and examined by Southern blot using an exon 3 λ5/ 14.1 probe. The results demonstrated the expected fragments representing the λ5-like genes and the lambda constant region genes, and did not reveal any altered fragments (Fig. 2).

The mutation in the paternal allele was confirmed by analyzing cDNA from the patient's bone marrow. RT-PCR, using primers from within exons 2 and 3, allowed the amplification of the 3′ portion of the patient's λ5/14.1 gene. The C to T basepair substitution at nucleotide 425 would be expected to destroy an MspI site at this locus. To determine the proportion of the transcripts derived from the maternal and paternal alleles, the RT-PCR products from a control and the patient were digested with MspI and examined in an agarose gel. Although all of the product from the normal control was digested, none of the product from the patient was cleaved, indicating that all of the transcripts were derived from the paternal allele (Fig. 3). The patient's PCR product was sequenced and revealed the three basepair substitutions specific to the 16.1 pseudogene sequence flanked by sequence characteristic of the functional λ5/14.1 gene (Fig. 1). These results provide strong support for the occurrence of a gene conversion event in the lambda locus.

The effects of the λ5/14.1 gene mutations on B cell development were examined in the patient's peripheral blood and bone marrow. In normal individuals, between 5 and 18% of the peripheral blood lymphocytes are B cells as defined by expression of CD19. Our past studies have shown that in patients with X-linked agammaglobulinemia, who have mutations in Btk, B cells represent between 0.01 and 0.10% of lymphocytes (34, 35), whereas in patients with mutations in mu heavy chain, B cells cannot be detected (5). In the patient with mutations in λ5/14.1, 0.06% of the peripheral blood lymphocytes expressed CD19. Like normal circulating B cells, these cells had low intensity expression of surface IgM and dim expression of CD38. By contrast, B cells seen in patients with mutations in Btk expressed an immature phenotype as defined by high intensity expression of both surface IgM and CD38 (34, 35).

Bone marrow cells from the patient and a normal age-matched control were stained in suspension with antibodies to surface immunoglobulin and CD19. Although a small number of CD19⁺ cells could be detected, there were almost no mature B cells as defined by coexpression of CD19 and surface immunoglobulin (Fig. 4,A). Over 85% of the CD19⁺ cells were positive for CD34 (Fig. 4,B), indicating a block at the transition between the pro–B cell and pre–B cell stage of differentiation. This block was also seen in permeabilized cells stained for terminal deoxynucleotidyl transferase (TdT) and surface or cytoplasmic IgM (Fig. 4 C). Although the number of TdT⁺ cells in the patient was comparable to the control, there were very few cells at the next stage of differentiation, cells which express cytoplasmic mu heavy chain. Bone marrow from λ5 knockout mice has markedly decreased expression of VpreB (36), suggesting that in the absence of λ5, VpreB is unstable. In bone marrow of controls, a mean of 82% of TdT⁺ cells was dimly positive for cytoplasmic VpreB, whereas, in the patient, 14% of the TdT⁺ cells were VpreB⁺.

To determine the functional consequences of the amino acid substitution in exon 3 of λ5/14.1, expression vectors for VpreB and the normal and mutant λ5/14.1 genes were introduced into COS7 cells by lipofection. In metabolically labeled cells transfected with VpreB and the normal or mutant λ5/14.1, both VpreB and λ5/14.1 could be immunoprecipitated from cell lysates using a monoclonal anti-VpreB antibody, demonstrating that the mutant as well as the normal λ5/14.1 could bind to VpreB. However, analysis of supernatants from cells transfected with the same vectors indicated that normal λ5/14.1 was secreted into the supernatant with VpreB, as previously described (13); whereas the mutant λ5/14.1 was not secreted (Fig. 5 A).

Because appropriate protein folding is required for protein secretion, and the amino acid substitution in the mutant λ5/14.1 was at a site that would be expected to influence tertiary structure, the capacity of the normal and mutant λ5/14.1 proteins to fold was compared in reducing and nonreducing conditions. As shown in Fig. 5 B, under nonreducing conditions, ∼50% of the normal λ5/14.1 moved through the gel more rapidly because of protein folding, but none of the mutant λ5/14.1 demonstrated altered migration. When coupled with the decreased expression of VpreB in the patient's bone marrow, these studies suggest that the mutant λ5/14.1 was improperly folded and degraded within the endoplasmic reticulum (37).

The results of these studies demonstrate that mutations in λ5/14.1 can result in profound B cell deficiency in humans. Transcription of the λ5/14.1 pseudogenes, 16.2 and Gλ1, has been described (18, 19), but it is not clear whether these transcripts are needed for normal development. The severe block in B cell differentiation in our patient indicates that the surrogate light chain pseudogenes in the patient could not compensate for the mutations in the λ5/14.1 gene. The fact that the patient had two different mutations in λ5/14.1 and that he was not a member of an isolated or inbred population, suggests that there may be other similar patients.

The mutation derived from the maternal allele in the patient was a C to T transition in the first exon resulting in the replacement of a wild-type glutamine with a premature stop codon. Premature stop codons in many genes, including Btk, β globin, and dihydrofolate reductase, are associated with faulty processing of the pre–messenger RNA and poor accumulation of the transcript in the cytoplasm (26, 38, 39), as was seen in this case. Thus, this mutation is functionally a null mutation.

The mutation in the paternal allele most likely occurred by gene conversion rather than by two unequal crossover events or three separate basepair substitutions. None of the three basepair substitutions seen in the patient's paternal allele were found individually in 100 normal people. Gene conversion is an uncommon mechanism of mutation; however, it has been suggested that gene conversion between the two highly homologous human fetal globin genes, Aγ and Gγ, explains the genetic variation within these tandemly duplicated genes (40). Immediate proximity of the donor and recipient DNA does not appear to be necessary for gene conversion. Although the functional von Willebrand factor gene is on chromosome 12, a portion of the gene is duplicated as a pseudogene on chromosome 22. In two families with von Willebrand disease, two different segments of the functional gene were replaced by portions of the pseudogene resulting in three basepair substitutions (41), as in our patient. The fact that gene conversion is used to generate antibody diversity in some species (42, 43) suggests that immunoglobulin domains may be unusually susceptible to this type of mutational event.

It is intriguing that the defects in λ5/14.1 seen in the patient described in this paper resulted in a disease more severe than that seen in mice lacking λ5 due to homologous recombination. One could postulate that the mutant λ5/ 14.1 protein produced in the patient's bone marrow might have a more deleterious effect than the absence of λ5 in the knockout mice. However, based on the observation that the patient's father, who was heterozygous for this mutation, had normal B cell numbers, the possibility of a dominant negative mutation is unlikely. The immune function in the λ5 knockout mice improved with time (8); it is possible that older patients with defects in λ5/14.1 may repair their B cell defects and antibody-forming capacity. Other explanations can be considered. The leaky phenotype in λ5-deficient mice has been attributed to B cell precursors in which light chain gene rearrangement preceded heavy chain gene rearrangement, thus negating the requirement for λ5 expression (8, 44). Although studies using human EBV-transformed B cell lines first suggested that rearrangement of light chain genes could occur before that of the heavy chain genes (45), the frequency or efficiency of this event may differ in the two species. There may be other factors that compensate for the lack of expression of λ5, and these factors may differ in the human compared to the mouse. Finally, the recovery of λ5-deficient mice is dependent on the expansion of early B cell precursors that have successfully rearranged both heavy and light chain genes. There may be differences in the regulation of this expansion in the human compared to the mouse.

Early B cell development in the mouse, but not the human, is highly dependent on signaling through the IL-7R (46, 47). By contrast, defects in Btk disrupt the pro–B cell to pre–B cell transition in the human, but not in the mouse (4, 25, 48). Our studies demonstrating the greater consequences of mutations in λ5/14.1 in the human compared to the mouse further emphasize the use of studying multiple models of B cell development. Comparison of the effects of mutations in the same gene in different species highlights the aspects of B cell signaling that are invariant and those that may be influenced by other genetic or environmental factors.

These studies were supported by grants from the National Institutes of Health AI25129, National Cancer Institute grant P30 CA21765, the Assisi Foundation, March of Dimes FY97-0384, American Lebanese Syrian Associated Charities, and by funds from the Federal Express Chair of Excellence. M.D. Cooper is a Howard Hughes Medical Institute Investigator.